The Next Generation Prep for Nasopharyngeal Exams USPTO Application #: 90522990
The uniqueness of the NPGDirect™ Anesthetizing Device uses a low-pressure wide angle misting nozzle tip to thoroughly irrigate and anesthetize the nasopharyngeal cavity.
Once the medication is fully dispensed, the spray tube is to be removed, and the hand held can remain in place adhered to the upper lip and then act as a protective sheathe.
This concept will allow other devices, of any combination i.e.: endoscope, biopsy needle, surgical fiber, culture swab, etc., to safely pass into the nasopharyngeal cavity thus preventing multiple insertions exposing the sinus to wide variety of pathogens not to mention exposing the patient to excessive pain associated with an otolaryngological procedure.
Details
- Gen III of the DirectCath™ will be called NPGDirect™
- With any nasopharyngeal examination, multiple insertions, subjects the patient to significant discomfort as well as pathogenic bacteria that can induce a sinus infection.
- Once the medication has been dispensed to thoroughly anesthetize the nasopharyngeal cavity, the concept is that the NPGDirect™ will act as a protective introducer sheathe.
- The scope of the NPGDirect™ is to then become a delivery device for endoscopes, surgical fibers, biopsy needles and/or punch, culture swabs etc.
- NPGDirect™ Anesthetizing Device is sterilized and packaged individually in a sealed pouch, if package is damaged or visibly tampered with, do not use.
- Our position is that the NPGDirect™ is essentially a long syringe, with the capability to “dispense” that being other medical devices such as a delivery device for endoscopes, surgical fibers, culture swabs, etc.
- Our goal is to have the FDA consider the NPGDirect™ device as a product line extension to the DirectCath™.
- Provided that the FDA concurs with the Class I approach for the DirectCath™ we will immediately begin the approval process for the NPGDirect™